Arpeggio

Arpeggio Biosciences Raises $17 Million in Series A Funding Led by Builders VC

Retrieved on: 
Wednesday, September 7, 2022
Biotechnology, Pharmaceutical, Genetics, Health, Machine learning, Asos, CEO, Technology, Agriculture, Disease, Factor X, MD, Database, Khosla Ventures, Therapy, Builder, Algorithm, List of life sciences, General partnership, Â, Pharmaceutical industry, Medical imaging, Arpeggio, Tencent

Arpeggio Biosciences, a preclinical therapeutics company whose technology targets transcriptional dysregulation in disease, and Builders VC, today announced a $17 million dollar Series A funding round, following a $3.2 million dollar seed round completed in 2020.

Key Points: 
  • Arpeggio Biosciences, a preclinical therapeutics company whose technology targets transcriptional dysregulation in disease, and Builders VC, today announced a $17 million dollar Series A funding round, following a $3.2 million dollar seed round completed in 2020.
  • Funding was led by Builders VC and will support ongoing development of Arpeggios drug pipeline as well as its transcription-monitoring technologies.
  • This Series A funding will enable us to continue our mission of discovering new therapies for diseases arising through dysregulation of transcription, said Joey Azofeifa, Ph.D., Founder and CEO, Arpeggio.
  • Using machine learning, Arpeggio reconstructs the biological networks affected by the molecule and matches the molecule to diseases where the compound could be therapeutically relevant.

Arpeggio Bio Raises $3.2 Million in Seed Funding and CEO Named to the 2020 Forbes 30 Under 30 List in Healthcare

Retrieved on: 
Wednesday, January 15, 2020
Health, Technology, Genetics, Software, Pharmaceutical, Biotechnology, Business, Articles, Music, Epigenetics, Genetic mapping, Lamarckism, Entrepreneurship, Arpeggio

Funding will support the ongoing development of a nascent RNA drug screen.

Key Points: 
  • Funding will support the ongoing development of a nascent RNA drug screen.
  • Were excited to have the support of our investors to allow us to continue our mission of helping bring new therapies to patients with epigenetically-driven diseases, said Joey Azofeifa, Ph.D., Founder and CEO, Arpeggio.
  • Driven by Arpeggios success, Dr. Azofeifa was recently named to the 2020 Forbes 30 Under 30 List in the Healthcare category , recognizing him as one of the countrys top young entrepreneurs.
  • These snapshots are then analyzed to reveal the biological networks that determine a drugs function and guide therapeutic development.